Iovance Biotherapeutics to Host First Quarter Financial Results Conference Call and Webcast on Thursday, May 6, 2021
Iovance Biotherapeutics will report its first quarter financial results on May 6, 2021, at 4:30 PM ET, followed by a conference call. The company specializes in T cell-based cancer immunotherapies, particularly tumor infiltrating lymphocyte (TIL) therapy, targeting solid tumors and blood cancers. Iovance has completed dosing in pivotal programs for metastatic melanoma and cervical cancer, and is conducting studies for non-small cell lung cancer and earlier stage cancers. Details of the conference call can be found on their website.
- Iovance has completed dosing in pivotal programs for metastatic melanoma and cervical cancer.
- Investigating TIL therapy in registration-supporting studies for non-small cell lung cancer.
- Engaging in clinical studies for earlier stage cancers in combination with approved treatments.
- None.
SAN CARLOS, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its first quarter financial results on Thursday, May 6, 2021. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. ET.
To participate in the conference call, please dial 1-800-773-2954 (domestic) or 1-847-413-3731 (international) and reference the access code 50155289. The live webcast can be accessed in the Investors section of the Company’s website at www.iovance.com. The archived webcast will also be available for one year in the Investors section at www.iovance.com.
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics aims to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers. Tumor infiltrating lymphocyte (TIL) therapy uses a patient’s own immune cells to attack cancer. TIL cells are extracted from a patient’s own tumor tissue, expanded through a proprietary process, and infused back into the patient. Upon infusion, TIL reach tumor tissue, where they attack cancer cells. The company has completed dosing in pivotal programs in patients with metastatic melanoma and cervical cancer. In addition, the company’s TIL therapy is being investigated in a registration-supporting study for the treatment of patients with locally advanced, recurrent or metastatic non-small cell lung cancer. Clinical studies are also underway to evaluate TIL in earlier stage cancers in combination with currently approved treatments, and to investigate Iovance peripheral blood lymphocyte (PBL) T cell therapy for blood cancers. For more information, please visit www.iovance.com.
CONTACTS
Iovance Biotherapeutics, Inc:
Sara Pellegrino, IRC
Vice President, Investor Relations & Public Relations
650-260-7120 ext. 264
Sara.Pellegrino@iovance.com
Solebury Trout:
Zara Lockshin (media)
646.378.2960
zlockshin@soleburytrout.com
